Vigil Neuroscience, Inc.

Vigil Neuroscience, Inc. (VIGL) priced its initial public offering on Jan 10, 2022 at $14.00 per share, below its $15.00–$17.00 range, raising $98M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $395.7M. Morgan Stanley was lead-left underwriter, joined by Jefferies, Stifel and Guggenheim. Goodwin Procter advised the company and Ropes & Gray advised the underwriters.

Vigil Neuroscience, Inc. develops microglia-targeted, disease-modifying therapeutics for rare and common neurodegenerative diseases. Its lead candidate, VGL101, is a monoclonal antibody TREM2 agonist for ALSP and other rare leukoencephalopathies.

Status

IPO

Ticker

VIGL

Exchange

Nasdaq Global Select

Priced

Jan 10, 2022

IPO price

$14.00

Price range

$15.00–$17.00

Raised

$98M

Market cap at IPO price

$395.7M

First filed

Nov 19, 2021

Underwriters

Morgan Stanley, Jefferies, Stifel and Guggenheim

Company counsel

Goodwin Procter

Underwriters' counsel

Ropes & Gray

Sector

Biotech & pharma

Country / state

MA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.